Fluanxol Depot Drug Interactions

Flupentixol may potentiate the sedative effect of alcohol and the effects of barbiturates and other CNS depressants. Antipsychotic agents may increase or reduce the effect of antihypertensive agents. They reduce the antihypertensive effect of guanethidine and similar agents.
Concomitant use of antipsychotics and lithium increases the risk of neurotoxicity. The metabolism of tricyclic antidepressants is inhibited by antipsychotics and vice versa.
Flupentixol may reduce the effect of levodopa and adrenergic agents.
Concomitant use of metoclopramide and piperazine increases the risk of extrapyramidal problems.
Co-administration of medicinal products known to prolong the QT interval is not recommended (see Precautions). Relevant classes include: class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol); certain antipsychotics (e.g. thioridazine); certain macrolides (e.g. erythromycin); certain antihistamines (e.g. terfenadine, astemizole); certain quinolone antibiotics (e.g. moxifloxacin).
The previously mentioned list is not exhaustive, and other medicinal products known to cause significant QT prolongation (e.g. cisapride and lithium) should be avoided.
Agents known to cause electrolyte disturbances such as thiazide diuretics (for hypokalemia) and agents known to increase the plasma levels of flupentixol should also be used with caution concurrently with flupentixol, as they may increase the risk of QT prolongation and malignant arrhythmias (see Precautions).